SIREN : 483080859
SPS PHARMA SERVICES is a French company founded 20 years ago, specialized in the sector Analyses, essais et inspections techniques. Based in ORLEANS (45100), this company of category PME shows in 2024 a revenue of 2.8 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicador | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Ingresos | 2 779 166 € | 2 374 306 € | 3 319 811 € | 3 154 901 € | 2 857 405 € | 2 031 607 € | 1 692 463 € | 1 132 746 € |
| Resultado neto | 255 202 € | -87 137 € | 843 192 € | 875 887 € | 1 146 640 € | 824 556 € | 542 008 € | 213 689 € |
| EBITDA | 166 390 € | -102 211 € | 997 942 € | 1 062 384 € | 1 415 526 € | 807 390 € | 652 669 € | 263 303 € |
| Margen neto | 9.2% | -3.7% | 25.4% | 27.8% | 40.1% | 40.6% | 32.0% | 18.9% |
In 2024, SPS PHARMA SERVICES achieves revenue of 2.8 M€. Over the period 2016-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +11.9%. Vs 2023, growth of +17% (2.4 M€ -> 2.8 M€). After deducting consumption (0 €), gross margin stands at 2.8 M€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 166 k€, representing 6.0% of revenue. Positive scissor effect: EBITDA margin improves by +10.3 pts, sign of improved operational efficiency. The operating margin remains fragile, requiring cost vigilance. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 255 k€, i.e. 9.2% of revenue. This profit can be retained or distributed to shareholders.
2 779 166 €
2 779 166 €
166 390 €
-9 648 €
255 202 €
6.0%
The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 86%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Cash flow represents 14.5% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
0.013%
86.485%
14.524%
0.0
47.9%
In 2024, the debt ratio of SPS PHARMA SERVICES (0.01) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
In 2024, the financial autonomy of SPS PHARMA SERVICES (86.5%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
In 2024, the repayment capacity of SPS PHARMA SERVICES (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
The liquidity ratio (= Current assets / Current liabilities) stands at 513.54. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 2.6x. Financial charges are adequately covered by operations.
513.542
2.578
In 2024, the liquidity ratio of SPS PHARMA SERVICES (513.54) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
In 2024, the interest coverage of SPS PHARMA SERVICES (2.6x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 37 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 65 days. Favorable situation: supplier credit is longer than customer credit by 28 days. Overall, WCR represents 147 days of revenue, i.e. 1.1 M€ to permanently finance. Over 2016-2024, WCR increased by +309%, requiring additional financing.
1 131 510 €
37 j
65 j
0 j
147 j
Indicative estimate only : the number of comparable transactions in this sector is limited (41 transactions). This range of 156 071€ to 1 304 839€ is provided for information purposes only and requires in-depth analysis to be confirmed.
This estimate is based on the analysis of 41 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare SPS PHARMA SERVICES with other companies in the same sector:
Voir toutes les statistiques du secteur Analyses, essais et inspections techniques
The revenue of SPS PHARMA SERVICES in 2024 is 2.8 M€.
Yes, SPS PHARMA SERVICES generated a net profit of 255 k€ in 2024.
The headquarters of SPS PHARMA SERVICES is located in ORLEANS (45100), in the department Loiret.
The tax return of SPS PHARMA SERVICES is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
SPS PHARMA SERVICES operates in the sector Analyses, essais et inspections techniques (NAF code 71.20B). See the 'Sector positioning' section above to compare the company with its competitors.